Applied Clinical Trials
Real examples from recent studies illustrate the risks associated with making such a delicate decision.
Peter Kleist
Advertisement
Peter Kleist, MD, MFPM RCP-UK, is a specialist in pharmaceutical medicine (CH) and medical director, Novartis Pharma Schweiz AG, Suedbahnhofstrasse 14d, CH-3007 Bern, Switzerland, email: [email protected].
Articles by Peter Kleist
Applied Clinical Trials
Adequate female representation is mandatory, but gender differences should not be overestimated.
Advertisement
Latest Updated Articles
Stopping a Trial Early for Treatment Benefit: Pros & ConsJanuary 1st 2007
Women and Trials: When Is Gender a Consideration?June 1st 2005
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Nature Medicine Retracts Viral Lung Cancer Timing Study After Four-Month Investigation
2
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
3
Real-Time Clinical Trial Oversight and the Infrastructure Gap: Q&A with Raj Indupuri, eClinical Solutions
4
ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion
5